1-7 of 7
Anton Belousov
Close
Sort by
Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel
Journal: Blood
Blood (2022) 140 (Supplement 1): 6448–6449.
https://doi.org/10.1182/blood-2022-157934
Published: 2022
Journal Articles

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Mark Bishton, Corinna Woestmann, Franck Morschhauser, Toby A. Eyre, Maria Shin, Aaron Schroeder, Anton Belousov, Haocheng Li, Andrea Knapp, Michael C. Wei, Enkhtsetseg Purev, Alessia Bottos
Journal: Blood
Blood (2022) 140 (Supplement 1): 3555–3556.
https://doi.org/10.1182/blood-2022-157256
Published: 2022
Journal Articles

Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Krishna V. Komanduri, Anton Belousov, Mark Dixon, James Relf, Maneesh Tandon
Journal: Blood
Blood (2022) 140 (Supplement 1): 9493–9495.
https://doi.org/10.1182/blood-2022-159561
Published: 2022
Journal Articles

Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy

Krishna V. Komanduri, Anton Belousov, Michelle Byrtek, Antonia Kwan, David Perez-Callejo, Chi-Chung Li, David Carlile, Bruce McCall, Tina Nielsen, Emily C. Piccione
Journal: Blood
Blood (2021) 138 (Supplement 1): 1459.
https://doi.org/10.1182/blood-2021-147303
Published: 2021
Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Genevive Hernandez, PhD, Ling-Yuh Huw, PhD, Anton Belousov, PhD, Deanna Wilson, MS, Hartmut Koeppen, MD PhD, Ron McCord, PhD, Kun Peng, PhD, Nancy L Bartlett, MD, Lihua E Budde, MD PhD, Sarit Assouline, MD, Loretta J. Nastoupil, MD MSc, Dok Hyun Yoon, MD PhD, Matthew J Matasar, MD, Brendan Bender, PhD, Antonia Kwan, MD PhD MRCPCH, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Shen Yin, PhD, Michael C Wei, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1585.
https://doi.org/10.1182/blood-2019-123933
Published: 2019
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5319.
https://doi.org/10.1182/blood-2019-123979
Published: 2019
Journal Articles

Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell Lines,

Gerhard Niederfellner, Olaf Mundigl, Alexander Lifke, Andreas Franke, Ute Baer, Helmut Burtscher, Daniela Maisel, Anton Belousov, K. Michael Weidner, PhD, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2011) 118 (21): 3721.
https://doi.org/10.1182/blood.V118.21.3721.3721
Published: 2011